Amgen Needs To Show Xgeva Does More Than Delay Bone Metastases, ODAC Says

Measurement of a downstream endpoint, such as delay in skeletal-related events, could have been better than radiographic scans to assess efficacy of denosumab in delaying bone metastases in high-risk castration-resistant prostate cancer patients, several ODAC members contend.